Biotech: Page 38
-
Getty Images
BenevolentAI appoints former Bayer R&D chief as CEO
The pharma veteran will take over the AI-focused biotech after a year that included a restructuring, job cuts and the resignation of its CFO.
By Kristin Jensen • Jan. 25, 2024 -
Getty Images
CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech
The sector’s first IPO of 2024 could be a positive signal for the handful of other companies that have recently laid out plans for initial public offerings.
By Gwendolyn Wu • Jan. 24, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
Novo strikes another obesity drug deal
The partnership with startup EraCal Therapeutics, a spinout of Harvard University and Zurich University, adds another prospect to Novo’s pipeline of weight loss drugs.
By Kristin Jensen • Jan. 24, 2024 -
Courtesy of Sanofi
Sanofi to buy Inhibrx in deal worth up to $2.2B
The acquisition will give Sanofi an experimental drug for alpha-1 antitrypsin deficiency, while the rest of Inhibrx's assets will be spun into a new company.
By Ned Pagliarulo • Jan. 23, 2024 -
Getty Images
Pharmas back Accent’s plan to make RNA-targeting cancer drugs
J&J and Bristol Myers joined the latest funding round for the startup, which was led by the newly launched Mirae Asset Capital Life Science.
By Gwendolyn Wu • Jan. 23, 2024 -
Courtesy of Coherus Biosciences
Coherus sells Lucentis biosimilar to Sandoz for $170M
The divestment, which includes sales and reimbursement staff, is part of Coherus’ plan to shift resources toward its R&D work in oncology.
By Delilah Alvarado • Jan. 22, 2024 -
Getty Images
Ionis says rare disease drug succeeds in late-stage HAE study
The medicine, called donidalorsen, reduced hereditary angioedema-related attacks in the Phase 3 trial. Several competing options to it are already available or in advanced testing, however.
By Ben Fidler • Jan. 22, 2024 -
Getty Images
Ikena Oncology to lay off 35% of staff
The cancer drugmaker is one of about a dozen biotechs that have announced workforce reductions so far in 2024.
By Delilah Alvarado • Jan. 19, 2024 -
Getty Images
A South Korean investment firm starts first US biotech fund
The $50 million fund, called Mirae Asset Capital Life Science, will back biotechnology companies from seed to Series C rounds.
By Gwendolyn Wu • Jan. 18, 2024 -
Getty Images
BridgeBio strikes drug royalty deal for cash infusion
The biotech will receive $500 million upon FDA approval of its rare disease drug acoramidis after selling 5% sales royalties to two investment firms.
By Ned Pagliarulo • Jan. 18, 2024 -
Getty Images
Comanche Biopharma raises $75M to fund preeclampsia drug testing
The biotech is developing an RNA-based therapy for what it describes as a root cause of the pregnancy-related complication, which affects millions of women.
By Delilah Alvarado • Jan. 17, 2024 -
Getty Images
Kyverna sets plans for IPO in test of biotech enthusiasm
The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.
By Kristin Jensen • Jan. 17, 2024 -
NIAID. (2019). "T Regulatory Cells" [Microscope image]. Retrieved from Flickr.
Tr1x, a new biotech, joins ‘Treg’ chase with $75M fundraise
The startup is focusing on immune cells called Tr1 cells, which it claims could be important in treating autoimmune conditions like graft-versus-host disease.
By Ben Fidler • Jan. 17, 2024 -
Permission granted by ClinicalMind
Sponsored by ClinicalMindSimplifying speaker engagement in Pharma: A holistic approach
Relationships with Speaker Bureau faculty are among the most important that a biopharmaceutical company nurtures.
Jan. 16, 2024 -
Brian Tucker / BioPharma Dive/BioPharma Dive
The biopharma industry outlook on 2024: Guarded optimism for a rebound
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By Ned Pagliarulo • Jan. 16, 2024 -
Getty Images
Allakos to lay off half of staff, scrap drug after study setback
The restructuring adds to a wave of industry layoffs. The Californian biotech is at least the third this year to plan a workforce reduction of 50% or more.
By Ben Fidler • Jan. 16, 2024 -
Win McNamee via Getty Images
Deep DiveWomen’s health companies, battling under-investment in research, see growing opportunity
While investment remains lower than in other areas of drug R&D, executives and VCs speak of progress for a field that’s been overlooked in the past.
By Delilah Alvarado • Jan. 16, 2024 -
David Dee Delgado via Getty Images
Backed by billionaires, a new biomedical institute tests an unorthodox approach
Arena BioWorks, which will be led by Harvard University scientist Stuart Schreiber, seeks to blend academic and venture capital drug research models.
By Ned Pagliarulo • Jan. 12, 2024 -
Permission granted by Recursion Pharmaceuticals
Q&ARecursion’s Chris Gibson on AI in biotech and ‘virtuous cycles’
The AI specialist caught the attention of many attendees to last week’s J.P. Morgan conference, where advanced computing’s impact on biotech was a much-discussed topic.
By Gwendolyn Wu • Jan. 12, 2024 -
Getty Images
Venture funding, dealmaking slowed in biotech last year: Pitchbook
Though the number of financings from private investors is down year over year, the size of those rounds has remained high, especially for drugmakers with human data in hand.
By Gwendolyn Wu • Jan. 11, 2024 -
Courtesy of Eisai
EU regulators to consult advisers in review of Eisai Alzheimer’s drug
As a result of the planned consultation, Eisai now expects an approval decision on Leqembi in Europe by the end of June, rather than March.
By Kristin Jensen • Jan. 11, 2024 -
anouchka via Getty Images
Newly optimistic, biotech investors weigh lessons of sector’s downturn
Investors and executives interviewed by BioPharma Dive at J.P. Morgan say new companies have to be leaner, hire more conservatively and focus on their first medicines quickly.
By Ben Fidler • Jan. 11, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
Radiopharma drugmakers spoke with BioPharma Dive about chasing Novartis in the hot field, while Bluebird’s CEO explained the company’s sickle cell therapy pricing.
By Ben Fidler , Ned Pagliarulo , Gwendolyn Wu • Jan. 10, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Pfizer’s tough sell, the next Karuna and building a biotech platform
Albert Bourla acknowledged Pfizer’s difficult 2023, while PureTech’s Daphne Zohar spoke with BioPharma Dive about building neuroscience startups.
By Ben Fidler , Delilah Alvarado • Jan. 9, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job
The chip maker struck a new deal with Amgen last Monday, while Sarepta brought news of strong sales to the J.P. Morgan Healthcare Conference.
By Gwendolyn Wu , Delilah Alvarado , Ben Fidler • Jan. 8, 2024
Previous
